Cryptome to chase opps in vascular field
19 September, 2005 by Helen SchullerMelbourne biopharma Cryptome Pharmaceuticals (ASX:CRP) has signed a collaboration agreement with the University of Virginia for the further discovery of compounds to treat 'vascular leak' -- a major component of inflammatory disorders and tissue damage associated with stroke, heart attacks and MS.
EvoGenix licenses leukaemia antibody
19 September, 2005 by Ruth BeranAntibody developer EvoGenix (ASX:EGX) has signed a licensing deal with Dinona for one of the South Korean biotech's anti-leukaemia antibodies.
CogState turns focus from biotech
19 September, 2005 by Helen SchullerMelbourne-based CogState (ASX:CGS) has distanced itself from the biotech sector, in a move that CEO Peter Bick described as "bowing to popular pressure that biotechs are highly risky and expensive businesses".
Avastra files for new BioWeld patent
16 September, 2005 by Ruth BeranSydney-based Avastra (ASX:AVS) has filed a provisional patent on the use of its BioWeld technology in conjunction with surgical glues and adhesives.
Starpharma investee Dimerix raises $1m
16 September, 2005 by Helen SchullerDimerix Bioscience has closed a series A capital raising worth almost AUD$1 million, and has revealed plans to accelerate the development of its new compounds created by applying its technologies to novel G-protein coupled receptor (GPCR) cluster targets.
Biota confirms Relenza orders from US, France, Hong Kong
16 September, 2005 by Ruth BeranMelbourne-based Biota Holdings (ASX:BTA) has confirmed that three more countries have placed orders for Relenza, the anti-flu drug developed by Biota and commercialised by Britain's GlaxoSmithKline (GSK).
Out, damned spot: wheat disease faces genetic nemesis
16 September, 2005 by Graeme O'NeillWheat stem rust, an inexorable pathogen of Australia's wheat belt since 1925, is destined to be run over by the genetic equivalent of a four-decker bus.
Avastra abandons BioWeld Tube clinical trials
13 September, 2005 by Ruth BeranBiomaterials company Avastra (ASX:AVS) is to abandon a clinical trial of its BioWeld Tube at Concord Repatriation and General Hospital, Sydney.
Antisense pleased with animal study of eye treatment
13 September, 2005 by Helen SchullerAntisense Therapeutics (ASX:ANP) has claimed successful results from animal studies targeting the growth hormone receptor with an antisense drug, designed to reduce the growth of new blood vessels that can lead to two eye diseases which are major causes of blindness.
Polartechnics CEO wants profits this year
13 September, 2005 by Ruth BeranAfter a turbulent year, Sydney-based Polartechnics (ASX:PLT) has seen a threefold increase in sales revenue for the 2004-05 financial year and is aiming to be profitable in the current year.
Peptech signs manufacturing deal
13 September, 2005 by Graeme O'NeillSydney antibody therapeutics developer Peptech (ASX:PTD) has signed an agreement with an unnamed biopharmaceuticals manufacturer to make its potent anti-inflammatory domain antibody (dAb) for preclinical and human clinical trials.
Unconfirmed Dutch order for Relenza boosts Biota
12 September, 2005 by Ruth BeranShares in Melbourne-based biopharma Biota Holdings (ASX:BTA) rose today in the wake of media reports that Holland has placed an order for Relenza, the anti-flu drug developed by Biota and commercialised by GlaxoSmithKline (GSK).
Prima's Arthron signs deal with US based Xencor
09 September, 2005 by Helen SchullerArthron, a subsidiary of Prima Biomed (ASX:PRR) has signed a license and option agreement with US biotechnology company Xencor to utilise Arthron's Fc receptor technology for enhancing the effect of anti-cancer antibodies.
Proteome to raise $10 million
09 September, 2005 by Ruth BeranSydney proteomics R&D company Proteome Systems (ASX:PXL) will raise about $10 million through the issue of over 33 million fully paid ordinary shares to institutional and professional investors in the UK, US and Australia at a price of $0.30 per share.
Alchemia heartened by results from GSK drug
08 September, 2005 by Ruth BeranThe market potential for Brisbane biopharma Alchemia's (ASX:ACL) generic version of GlaxoSmithKline's (GSK) anti-blood clot drug Arixtra has been significantly enhanced by clinical trial results finding that the Arixtra is safer and as effective as Sanofi-Aventis' Lovenox, the traditional therapy used for preventing heart attacks, death and ischemia in people with serious heart conditions.
